Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03050463
Recruitment Status : Recruiting
First Posted : February 13, 2017
Last Update Posted : June 19, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Stanford University

Brief Summary:
The investigators hope to gain a better understanding of the influence of affect reactivity and regulation on the decision of newly diagnosed breast cancer patients to choose bilateral mastectomy. The information gained can help develop an intervention to enable management of cancer-related anxiety by non-surgical means.

Condition or disease Intervention/treatment
Healthy Subject Stage 0 Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Stage IIB Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Procedure: Biospecimen Collection Procedure: Functional Magnetic Resonance Imaging Other: Questionnaire Administration

Detailed Description:

PRIMARY OBJECTIVES:

I. Examine affect reactivity and regulation among women with a recent diagnosis of breast cancer in comparison to healthy controls.

II. Relate affect reactivity and regulation to choice of bilateral mastectomy (BLM).

SECONDARY OBJECTIVES:

I. Assess long term functioning correlates of BLM decision and affect reactivity and regulation.

OUTLINE: Study plans to recruit total of 170 women. Participants will be assigned to 3 arms. For women diagnosed with breast cancer (total of 130) 65 with BLM as part of their cancer treatment and 65 non-BLM. The 3rd arm being 40 women with no cancer diagnosis as controls.

Study protocol will be the same for all 170 Study participants. Active participation by each participant will be approximately 8 hours at baseline and 2 hours at 6, 12, and 18-month follow-ups. Baseline assessment involve completing a set of questionnaires, participating in various tasks while undergoing an MRI scan of the head, providing saliva samples and I tube of blood. Follow-up assessments involve completing a set of questionnaires and saliva collection, all can be done at home.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 170 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions
Actual Study Start Date : August 2016
Estimated Primary Completion Date : January 2020
Estimated Study Completion Date : January 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
breast cancer with bilateral mastectomy
This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
Procedure: Biospecimen Collection
Undergo blood and saliva sample collection

Procedure: Functional Magnetic Resonance Imaging
Undergo fMRI related tasks
Other Names:
  • fMRI
  • FUNCTIONAL MRI

Other: Questionnaire Administration
Ancillary studies

breast cancer without bilateral mastectomy
This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
Procedure: Biospecimen Collection
Undergo blood and saliva sample collection

Procedure: Functional Magnetic Resonance Imaging
Undergo fMRI related tasks
Other Names:
  • fMRI
  • FUNCTIONAL MRI

Other: Questionnaire Administration
Ancillary studies

healthy subjects
Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
Procedure: Biospecimen Collection
Undergo blood and saliva sample collection

Procedure: Functional Magnetic Resonance Imaging
Undergo fMRI related tasks
Other Names:
  • fMRI
  • FUNCTIONAL MRI

Other: Questionnaire Administration
Ancillary studies




Primary Outcome Measures :
  1. Explicit Affect Reactivity and Regulation Measured Using functional MRI (fMRI) Reactivity Probes [ Time Frame: Up to 18 months ]
    Multivariate regression analysis will be used to examine affect reactivity among women with a recent diagnosis of breast cancer in comparison to healthy controls at baseline. Functional data will be collected on the explicit affect regulation task (20 minutes) and explicit cancer related affect regulation task (8 minutes). Affect reactivity and cancer-related affect reactivity will be defined by WATCH negative minus WATCH neutral and by WATCH cancer-related negative and WATCH neutral contrast. The larger this value, the greater the affect reactivity. Explicit affect regulation will defined by WATCH negative minus REAPPRAISE negative, and by WATCH negative minus REAPPRAISE cancer-related negative contrasts. The greater this value, the less successful explicit regulation is.

  2. Implicit Affect Reactivity and Regulation Measured Using fMRI Reactivity Probes [ Time Frame: Up to 18 months ]
    Multivariate regression analysis will be used to examine affect reactivity among women with a recent diagnosis of breast cancer in comparison to healthy controls at baseline. Functional data will be collected on the implicit affect regulation task (13 minutes) and implicit cancer-related affect regulation task (13 minutes). Affect reactivity and cancer-related affect reactivity will be defined by incongruent minus congruent trials and incongruent cancer minus congruent cancer-related trials. The greater this value, the more affect reactivity there is. Implicit affect regulation for general affective content will be calculated by post-congruent incongruent trials minus post-incongruent incongruent trials. Similarly, implicit affect regulation for cancer related content will be calculated from the post-congruent incongruent trials minus post-incongruent incongruent trials in the cancer-related adaptation of the task. The greater this value, the less successful implicit regulation is.


Secondary Outcome Measures :
  1. Diurnal Slope of Cortisol [ Time Frame: Up to 18 months ]
    Affect management is associated with the diurnal slope of cortisol. The stress of a breast cancer diagnosis and subsequent treatment choices is bound to affect hormonal stress response systems, such as the hypothalamic-pituitary-adrenal axis (HPA). Cortisol levels, measured reliably in saliva, are a meaningful and accessible way of assessing physiological stress response. Salient to this study of affect regulation, the investigators have found that flatter diurnal cortisol slope is associated with higher repressive-defensiveness and less sustained expression of primary negative affect in a group setting.

  2. BLM decision and affective distress [ Time Frame: Up to 18 months ]
    Longitudinal trajectories of affective distress are examined. For this, The Contralateral Prophylactic Mastectomy (CPM) survey consists of 23 items related to decision making, knowledge, risk perceptions, and worry about breast cancer. It was developed based on expert knowledge measuring decision making, risk perceptions, and knowledge outcomes in patients with breast cancer. It showed in a recent study that choice of CPM is related to significant anxiety about cancer coupled with overestimation of the risk of recurrence and therefore of the benefit of the procedure. This will be used to study the link between affect reactivity and regulation and cognitive distortion about risks and benefits.

  3. Functional status as a predictor of longitudinal progression [ Time Frame: Up to 18 months ]
    Functional status is assessed through self-report measures. The "Ways of Coping Checklist" was developed to assess eight fundamental dimensions of the coping process: confrontation, distancing, self-control, seeking social support, accepting responsibility, escape/avoidance, planful problem solving, and positive reappraisal. These dimensions measure two general functions of coping, problem-focused coping and emotion-focused coping. Problem-focused coping is aimed at doing something to change the stressful situation for the better, whereas emotion- focused coping is aimed at regulating emotional distress


Other Outcome Measures:
  1. Choice of BLM and reliance on information from nonmedical sources assessed using the Rosenberg questionnaire [ Time Frame: Up to 18 months ]
    As an exploratory analysis, using logistic regression analysis, an examination of whether women who choose BLM report more reliance on information from nonmedical sources such as media and the internet than on medical professionals and family/friends (Rosenberg Questionnaire (29), question 23) will be conducted.


Biospecimen Retention:   Samples With DNA
blood and saliva


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
patients with stage 0-III breast cancer at Stanford Cancer Center, as well as healthy subjects
Criteria

Inclusion Criteria:

Women Diagnosed with breast cancer

  • Female
  • Age 18 or older
  • Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre and during cortisol sampling (based on PI's clinical judgement)
  • Agree to taking saliva samples and having fMRI scan
  • No contraindications to MRI imaging (like ferromagnetic metal in their body)
  • Proficiency in English sufficient to complete questionnaires and follow instructions during the fMRI assessments
  • US Citizen or resident able to receive payment legally
  • Documented stage 0-III breast cancer
  • Unilateral breast tumors

Controls

  • Female
  • Age 18 or older
  • Agree to suspend treatments containing Benzodiazepines and steroids up to 2 weeks pre and during cortisol sampling (based on PI's clinical judgement)
  • Agree to having saliva samples and fMRI scan
  • No contraindications to MRI imaging (like ferromagnetic metal in their body)
  • Proficiency in English sufficient to complete questionnaires and follow instructions during the fMRI assessments
  • US Citizen or resident able to receive payment legally

Exclusion Criteria:

Women Diagnosed with breast cancer

  • Other active cancers within the past 10 years other than squamous cell carcinoma of the skin
  • Pregnant
  • Any significant neurologic disease, such as dementia, multi-infarct dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain injury
  • Hearing impaired
  • Current untreated psychosis, or bipolar disorder, or substance/alcohol abuse/dependence
  • Current use of psychotropic (based on PI's clinical judgement) medication 5 or more days a week

Controls

  • Cancer diagnosis, current or past
  • Pregnant
  • Any significant neurologic disease, such as dementia, multi-infarct dementia, Parkinson's or Huntington's disease, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, stroke, or traumatic brain injury
  • Hearing impaired
  • Current untreated psychosis, or bipolar disorder, or substance/alcohol abuse/dependence
  • Current use of psychotropic (based on PI's clinical judgement) medication 5 or more days a week
  • Breast cancer diagnosis in 1 first degree relative or 2 or more second degree relatives
  • Ovarian cancer diagnosis in 1 first or second degree relative

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03050463


Contacts
Layout table for location contacts
Contact: Bita Nouriani 650-723-8479 treatmentdecisionstudy@stanford.edu

Locations
Layout table for location information
United States, California
Stanford University, School of Medicine Recruiting
Palo Alto, California, United States, 94304
Contact: Bita Nouriani    650-723-8479    treatmentdecisionstudy@stanford.edu   
Principal Investigator: David Spiegel         
Sponsors and Collaborators
Stanford University
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: David Spiegel Stanford University

Layout table for additonal information
Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT03050463     History of Changes
Other Study ID Numbers: BRSADJ0030
NCI-2016-01547 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
BRSADJ0030 ( Other Identifier: Stanford Cancer Institute )
U01CA197282 ( U.S. NIH Grant/Contract )
First Posted: February 13, 2017    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: June 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Breast Carcinoma In Situ
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Carcinoma in Situ
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type